Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectors
about
Nonhuman primate models for HIV/AIDS vaccine developmentPoxvirus vectors as HIV/AIDS vaccines in humansThe evolution of poxvirus vaccinesImproved NYVAC-based vaccine vectorsDevelopment of replication-competent viral vectors for HIV vaccine delivery.Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C.Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigensImproving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling PathwaysInterleukin-1- and type I interferon-dependent enhanced immunogenicity of an NYVAC-HIV-1 Env-Gag-Pol-Nef vaccine vector with dual deletions of type I and type II interferon-binding proteins.Cross-presentation and genome-wide screening reveal candidate T cells antigens for a herpes simplex virus type 1 vaccine.Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman PrimatesVirus inhibition activity of effector memory CD8(+) T cells determines simian immunodeficiency virus load in vaccinated monkeys after vaccine breakthrough infection.Removal of vaccinia virus genes that block interferon type I and II pathways improves adaptive and memory responses of the HIV/AIDS vaccine candidate NYVAC-C in miceCD4 T follicular helper cell dynamics during SIV infectionEnhancing poxvirus vectors vaccine immunogenicity.Vaccinomics, adversomics, and the immune response network theory: individualized vaccinology in the 21st century.Attenuation and immunogenicity of host-range extended modified vaccinia virus Ankara recombinants.The canarypox virus vector ALVAC induces distinct cytokine responses compared to the vaccinia virus-based vectors MVA and NYVAC in rhesus monkeys.Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens.Innate immune recognition of poxviral vaccine vectors.New developments in an old strategy: heterologous vector primes and envelope protein boosts in HIV vaccine design.A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles.HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-SpeciPerpetuation of vaccine memory T cell responses against SIV/HIV.Meeting report VLPNPV: Session 5: Plant based technology.
P2860
Q26861148-C1BD6E8F-3EAE-4402-A255-BA1328C05747Q26995078-21A9E393-369E-489C-93C8-27137F126D31Q26995905-562C8CB2-A5DF-49E6-8B6A-8D10565E7F93Q28742982-6D58DE15-6811-4EE6-8A19-2D5263DB74F1Q33694226-55E1D294-096C-4104-B77C-07AC83CCFC27Q34247289-7CE12CCD-AC41-46E7-9DD6-783F4236A821Q34465228-0CCECBDC-101E-42AD-8C0A-161F77B84669Q34796206-DA284152-CD2E-4E35-9280-159378618B1CQ35488175-2AAC4CA5-8A4A-4A67-B002-BECBDF2CC505Q35699002-EBC838D2-C3C1-4CF4-B17A-B99AC70F5943Q35914311-9B408BB6-CCDA-4F12-9204-03446F7EDB5CQ35943537-78177B62-E84E-4FA3-AF19-58253198C710Q35943846-3C6C13E0-9483-4004-97FF-D57FE0973190Q36190736-3735FBB5-0D23-43F8-B889-0A85F3BB2EE3Q36978452-7C7BAC9D-9686-4A08-9083-865F7D93DB2AQ37119456-090BE8CC-F1A9-4165-9334-049017E15508Q37209483-D644147F-AFD2-45DB-B601-D419438574A9Q37547241-132602C8-133E-4CE4-9ADA-5D456635712FQ37643731-9B4CEC9F-29C4-4AFF-9FD3-CE3543DACAC4Q37944321-CCBB653F-5449-458F-AA63-68D44657E10BQ38748193-1CF68839-2D21-40DB-8968-8AE4BE3BB3DCQ40220988-9C93E6E6-37AA-4DE9-A1BE-8ABEA7D5348DQ40339467-6B450A38-B2BC-42AF-AB6D-7A933978A55FQ41814436-47B30367-0309-4AAD-B2A2-E6B1464071A7Q42346870-07DDC580-766E-47DC-94C0-364E8D30B19F
P2860
Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectors
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Improved innate and adaptive i ...... otein expressing NYVAC vectors
@ast
Improved innate and adaptive i ...... otein expressing NYVAC vectors
@en
Improved innate and adaptive i ...... otein expressing NYVAC vectors
@nl
type
label
Improved innate and adaptive i ...... otein expressing NYVAC vectors
@ast
Improved innate and adaptive i ...... otein expressing NYVAC vectors
@en
Improved innate and adaptive i ...... otein expressing NYVAC vectors
@nl
prefLabel
Improved innate and adaptive i ...... otein expressing NYVAC vectors
@ast
Improved innate and adaptive i ...... otein expressing NYVAC vectors
@en
Improved innate and adaptive i ...... otein expressing NYVAC vectors
@nl
P2093
P2860
P50
P1433
P1476
Improved innate and adaptive i ...... otein expressing NYVAC vectors
@en
P2093
Abdelali Filali-Mouhim
Anke Redeker
Beatriz Perdiguero
Bertram L Jacobs
Cornelis J M Melief
Elias K Haddad
Esther D Quakkelaar
Ferry Ossendorp
Jean-Philippe Goulet
Jim Tartaglia
P2860
P304
P356
10.1371/JOURNAL.PONE.0016819
P407
P50
P577
2011-02-15T00:00:00Z